Thus, this work indicates that elevated AXL expression can mediate docetaxel resistance and provide a rationale for the clinical evaluation of anti-AXL therapeutics for the treatment of docetaxel-resistant prostate cancer. The gene discussed is AXL; the disease is prostate carcinoma.